BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
Clinical Trial Update: BriaCell Therapeutics is conducting a pivotal Phase 3 study of its Bria-IMT™ combination therapy with an immune checkpoint inhibitor for metastatic breast cancer, with patient enrollment expected to complete by mid-2025 and interim data analysis planned after 144 deaths occur.
Safety and Efficacy: No serious adverse events related to Bria-IMT™ have been reported, and positive results from the study could lead to full approval and marketing authorization for the treatment in patients who have not responded to existing therapies.
Trade with 70% Backtested Accuracy
Analyst Views on BCTXW
No data
About the author
BRIACELL THERAPEUTICS CORP TO ALLOCATE UP TO $3 MILLION FOR BRIAPRO RESEARCH AND DEVELOPMENT
Funding Announcement: BRIACELL Therapeutics Corp has announced a funding initiative to provide up to $3 million for research and development (R&D) purposes.
Purpose of Funding: The funding is aimed at advancing the company's therapeutic programs and enhancing its research capabilities.
BRIACELL THERAPEUTICS CORP - BRIAPRO TO REMIT 2% ROYALTIES TO UMBC AFTER COMMERCIALIZATION
Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.
Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.
BRIACELL AND BRIAPRO SIGN ASSET PURCHASE AGREEMENT FOR EXCLUSIVE LICENSE OF SOLUBLE CD80
Agreement Overview: A new agreement has been reached for the purchase of exclusive soluble CD80 licenses.
Parties Involved: The agreement involves BRIACELL and a partner entity, indicating a strategic collaboration in the biotech sector.
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025
Bria-OTS+ Platform Overview: BriaCell Therapeutics has showcased its next-generation Bria-OTS+ platform, which demonstrates rapid and durable anti-cancer activity by engaging both innate and adaptive immune responses in preclinical models.
Preclinical Findings: The platform's lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have shown strong immune activation and sustained anti-cancer responses, indicating potential for prolonged clinical benefits.
Broad Applicability: The positive results from Bria-BRES+ and Bria-PROS+ suggest the Bria-OTS+ platform could be expanded to treat other solid tumors, highlighting its ability to generate potent immune responses across various cancer types.
Future Clinical Trials: BriaCell plans to confirm these preclinical findings in upcoming Phase 1/2a clinical studies, with Bria-PROS+ supported by a $2 million National Cancer Institute award.
BRIACELL THERAPEUTICS CORP TO ALLOCATE UP TO $3 MILLION FOR BRIAPRO RESEARCH AND DEVELOPMENT
Funding Announcement: BRIACELL Therapeutics Corp has announced a funding initiative to provide up to $3 million for research and development (R&D) purposes.
Purpose of Funding: The funding is aimed at advancing the company's therapeutic programs and enhancing its research capabilities.
BRIACELL THERAPEUTICS CORP - BRIAPRO TO REMIT 2% ROYALTIES TO UMBC AFTER COMMERCIALIZATION
Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.
Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.
BRIACELL AND BRIAPRO SIGN ASSET PURCHASE AGREEMENT FOR EXCLUSIVE LICENSE OF SOLUBLE CD80
Agreement Overview: A new agreement has been reached for the purchase of exclusive soluble CD80 licenses.
Parties Involved: The agreement involves BRIACELL and a partner entity, indicating a strategic collaboration in the biotech sector.
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025
Bria-OTS+ Platform Overview: BriaCell Therapeutics has showcased its next-generation Bria-OTS+ platform, which demonstrates rapid and durable anti-cancer activity by engaging both innate and adaptive immune responses in preclinical models.
Preclinical Findings: The platform's lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have shown strong immune activation and sustained anti-cancer responses, indicating potential for prolonged clinical benefits.
Broad Applicability: The positive results from Bria-BRES+ and Bria-PROS+ suggest the Bria-OTS+ platform could be expanded to treat other solid tumors, highlighting its ability to generate potent immune responses across various cancer types.
Future Clinical Trials: BriaCell plans to confirm these preclinical findings in upcoming Phase 1/2a clinical studies, with Bria-PROS+ supported by a $2 million National Cancer Institute award.
